Celldex Therapeutics stock (US15117B1035): Wells Fargo raises price target to $54

Wells Fargo maintained its rating on Celldex Therapeutics and lifted the price target to $54 from $38, signaling optimism on the biotech's clinical pipeline including barzolvolimab.

Celldex Therapeutics disclosed third-quarter 2025 financial results in its 10-Q filing, showing no revenue and elevated operating expenses amid advancing clinical programs, according to Stock Titan as of August 2025. Separately, Wells Fargo raised its price target on the stock to $54 from $38 while maintaining its rating, as reported by GuruFocus.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Celldex Therapeutics, Inc.
• Sector/industry: Biotechnology
• Headquarters/country: United States
• Core markets: Immunology and mast cell-mediated diseases
• Key revenue drivers: Antibody therapeutics pipeline
• Home exchange/listing venue: Nasdaq (CLDX)
• Trading currency: USD

Celldex Therapeutics: core business model

Celldex Therapeutics focuses on developing antibody-based therapeutics targeting immunology and mast cell-mediated diseases. The company's lead candidate, barzolvolimab, is in clinical trials for conditions like eosinophilic esophagitis (EoE). On August 19, 2025, Celldex issued a press release via Form 8-K detailing positive Phase 2 results for barzolvolimab in EoE, according to Stock Titan as of August 2025. This kit ligand inhibitor aims to address chronic inflammatory diseases of the esophagus.

The business model relies on advancing its pipeline through clinical stages toward regulatory approval and commercialization. Celldex operates as a clinical-stage biotech with no approved products generating revenue yet, funding operations via equity financings and partnerships. Its SEC filings highlight ongoing trials and corporate updates for US investors tracking Nasdaq-listed biotechs.

Main revenue and product drivers for Celldex Therapeutics

Future revenue hinges on barzolvolimab and other pipeline assets. The Q3 2025 10-Q reported zero revenue for the quarter ended September 30, 2025, with higher R&D spend on clinical advancements, per Stock Titan as of 2025. Positive EoE data from Phase 2 could support progression to Phase 3, potentially driving milestone payments or licensing deals.

Additional drivers include other immunology programs. Celldex's filings note material events like stock financings to support development, relevant for US investors eyeing biotech growth in inflammatory disease treatments.

Industry trends and competitive position

The biotech sector sees rising demand for targeted immunotherapies in rare diseases like EoE. Celldex competes with players developing mast cell modulators, positioning barzolvolimab as a potential differentiator based on Phase 2 outcomes reported August 19, 2025. US market exposure is strong via Nasdaq listing, appealing to domestic investors.

Why Celldex Therapeutics matters for US investors

As a Nasdaq-listed biotech, Celldex offers US investors exposure to immunology innovation. Its pipeline targets underserved areas like mast cell diseases, with clinical readouts influencing stock volatility. Q3 2025 results and analyst updates underscore its role in the US biotech landscape.

Conclusion

Celldex Therapeutics advances its barzolvolimab pipeline amid Q3 2025 results showing no revenue but ongoing clinical investment. Wells Fargo's price target hike to $54 reflects pipeline optimism. Investors monitor upcoming trial data and financings for this Nasdaq biotech.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.